CCM
CRL icon

Cullen Capital Management’s Charles River Laboratories CRL Stock Holding History

Cullen Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,800
Closed -$229K – 209
2014
Q1 		$229K Hold
3,800
– – 0.01% 191
2013
Q4 		$202K Buy
+3,800
New +$191K 0.01% 193
2013
Q3 		– Sell
-5,285
Closed -$217K – 198
2013
Q2 		$217K Buy
+5,285
New +$226K 0.01% 171

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Cullen Capital Management's CRL Position: Q2 2014 in Review

Cullen Capital Management sold out of Charles River Laboratories (CRL) in Q2 2014, closing a stake of 3,800 shares — an estimated $229K sold.

Cullen Capital Management first reported a position in CRL in Q2 2013 and held it in 3 quarters. The position peaked at $229K in Q1 2014. 262 funds tracked by Wall St. Rank hold CRL as of Q2 2014.

  • Cullen Capital Management reported no remaining Charles River Laboratories position as of Q2 2014 after selling out during the quarter.
  • Cullen Capital Management sold 3,800 Charles River Laboratories shares in Q2 2014, an estimated $229K.
  • Cullen Capital Management first reported a position in Charles River Laboratories in Q2 2013 and held it in 3 quarters.
  • Cullen Capital Management's Charles River Laboratories position peaked at $229K in Q1 2014.
  • 262 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2014.

Based on Cullen Capital Management's 13F filing for Q2 2014, filed 11 Aug 2014.